Literature DB >> 1234374

The surgical therapy of malignant melanomas.

L I Goldman.   

Abstract

Survival from malignant melanoma has been serially followed over a long period of time. A summation of this information is seen in Table 5. The steadily improving 5- and 10-yr disease-free intervals in stage I disease probably represents a combination of increased awareness of early lesions and the application of aggressive, initial surgical treatment. The ominous and essentially unchanged prognosis in stage II disease reinforces this goal. Suspicion and gross recognition of early melanoma is essential. Adequate biopsy with the appropriate classification provides the surgeon with insight into the correct therapy. This usually entails wide, three-dimensional excision and wound closure by free skin-grafting. Regional lymphadenectomy is performed whenever anatomical and microscopic conditions dictate the need. The roles of amputation, regional perfusion, and adjuvant therapy require clarification. Studies are being pursued to provide firm data concerning the value of these methods.

Entities:  

Mesh:

Year:  1975        PMID: 1234374

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  At least one centimetre for each millimetre.

Authors:  F H Rampen
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-29

2.  The extent of primary melanoma excision. A re-evaluation--how wide is wide?

Authors:  D R Aitken; K Clausen; J P Klein; A G James
Journal:  Ann Surg       Date:  1983-11       Impact factor: 12.969

3.  Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma.

Authors:  D F Roses; M N Harris; D Rigel; Z Carrey; R Friedman; A W Kopf
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

4.  The accuracy of predicting lymph nodes metastases in malignant melanoma by clinical examination and microstaging.

Authors:  L I Goldman; W H Clark; E A Bernardino; A M Ainsworth
Journal:  Ann Surg       Date:  1976-11       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.